Misera Agata, Marlicz Wojciech, Podkówka Albert, Łoniewski Igor, Skonieczna-Żydecka Karolina
Department of Psychiatry, Pomeranian Medical University in Szczecin, Szczecin 71-460, Poland.
Department of Gastroenterology, Pomeranian Medical University in Szczecin, Szczecin 71-252, Poland.
Microbiome Res Rep. 2024 Sep 10;3(4):48. doi: 10.20517/mrr.2023.81. eCollection 2024.
() is a promising candidate bacterium for stress management due to its beneficial effects on the microbiota-gut-brain axis (MGBA). As a well-known mucin-degrading bacterium in the digestive tract, has demonstrated significant benefits for host physiology. Recent research highlights its potential in treating several neuropsychiatric disorders. Proposed mechanisms of action include the bacterium's outer membrane protein Amuc_1100 and potentially its extracellular vesicles (EVs), which interact with host immune receptors and influence serotonin pathways, which are crucial for emotional regulation. Despite its potential, the administration of probiotics containing faces technological challenges, prompting the development of pasteurized forms recognized as safe by the European Food Safety Authority (EFSA). This review systematically examines the existing literature on the role of in stress management, emphasizing the need for further research to validate its efficacy. The review follows a structured methodology, including comprehensive database searches and thematic data analysis, to provide a detailed understanding of the relationship between stress, microbiota, and therapeutic potential.
由于其对微生物群-肠道-脑轴（MGBA）具有有益作用，（）是一种用于应激管理的有前景的候选细菌。作为消化道中一种著名的黏蛋白降解细菌，已证明对宿主生理有显著益处。最近的研究突出了其在治疗几种神经精神疾病方面的潜力。提出的作用机制包括该细菌的外膜蛋白Amuc_1100以及可能的细胞外囊泡（EVs），它们与宿主免疫受体相互作用并影响血清素途径，而血清素途径对情绪调节至关重要。尽管有潜力，但含有（）的益生菌的施用面临技术挑战，这促使了被欧洲食品安全局（EFSA）认可为安全的巴氏杀菌形式的开发。本综述系统地研究了关于（）在应激管理中的作用的现有文献，强调需要进一步研究以验证其疗效。该综述遵循结构化方法，包括全面的数据库搜索和主题数据分析，以详细了解应激、微生物群和（）治疗潜力之间的关系。
